Clinical Trial Update: A Phase I Study of BR108 in Hematological Malignancies [Phase 1]

View source ↗

Summary

A Phase I study of BR108 in hematologic malignancies has been terminated, with no further trial activity reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• BR108

Snippet

Sponsor: BioRay Pharmaceutical Co., Ltd. | Conditions: Hematologic Malignancy | Phase 1 | Status: TERMINATED